National Policy Forum 8 th October 2012, New Delhi Prithviraj Nath CUTS Calcutta Resource Centre Findings and Inferences from project- BRCC.

Slides:



Advertisements
Similar presentations
Ethics review and oversight for better governance of health research Amar Jesani Indian Journal of Medical Ethics Centre for Studies in Ethics and Rights.
Advertisements

Group 3 Irrational use of Medicine and medical technology.
Sakthivel Selvaraj, Habib Hasan, Preeti Kumar, Maulik Chokshi Public Health Foundation of India, India 1.
ISSUES AND CHALLENGES IN REGULATION OF PRIVATE SECTOR Study of Private hospitals In Maharashtra Dr Ritu Khatri and Padma Deosthali CEHAT.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.
Gunjan Organisation for Community Development. Goal: To stimulate better business to achieve sustainable development objectives in India Objectives: 
EXPLORING THE INTERPLAY BETWEEN BUSINESS REGULATION & CORPORATE CONDUCT (BRCC) Rijit Sengupta Jaipur, 13 th April 2012.
Promoting CSR in Albania Global Compact and Corporate Social Responsibility Project October 19, 2012 United Nations Development Programme.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
CSR Practices: Problems and Prospects (A Case of Jharkhand State) Dr
DEPARTMENT OF HUMAN SETTLEMENTS- SANITATION INPUTS ON NATIONAL WASTE MANAGEMENT STRATEGY 29 MAY 2012 By Mandisa Mangqalaza.
© CSR Asia 2010 ISO Richard Welford CSR Asia
Corporate Governance Group
Rethinking Business Responsibility In India: a review of Pharmaceutical & Private Healthcare sectors Vikash Batham, CUTS International Developing an Inclusive.
Access to Medicine Index 3 rd International Conference for Improving the Use of Medicines Poster 599 Tuesday 15 th November 2011.
Wenxin Zhang Department of Civic Design University of Liverpool
The Pharmaceutical Market in Mauritius : a Case for Stronger Regulation Mosadeq Sahebdin.
Regulation & Implementation of Mobile Internet Quality of Service: Role & Scope of Civil Society Organisations PRESENTATION BY: NEHA TOMAR, RESEARCH ASSOCIATE,
THE PRESENT EXPERIENCE AND CHALLENGES BEFORE THE BULGARIAN HEALTH INSURANCE SYSTEM IN THE FIELD OF HOSPITAL CARE Jeni Nacheva Director of Department for.
30 th October 2014, New Delhi BUSINESS RESPONSIBILITY GUIDELINES FOR PHARMACEUTICAL SECTOR IN INDIA.
Survey on Corporate Citizenship in Hong Kong ( )
Project Launch Meeting National Competition Policy and Economic Growth in India - ComPEG Presentation on Project Overview Natasha Nayak, CUTS.
WELCOME RDC/ CUTS/ BRCC-Gujarat : Promoting Responsible Business in Pharmaceuticals and Private Healthcare Sector STATE LEVEL STAKEHOLDER DIALOGUE.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Copyright © 2008 McGraw-Hill Ryerson Ltd.1 Chapter Twelve Corporate Governance Canadian Business and Society: Ethics & Responsibilities.
CORPORATE GOVERNANCE Regulatory expectations and current good practice Charles Cattell The Cattellyst Consultancy.
Medical Device Compliance Congress: Emerging Compliance Issues in Asia Anne Trimmer.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Corporate Governance in the Caribbean Environment “The Caribbean Corporate Governance Forum” Trevor E Blake General Manager – ECSE.
COGITA is made possible by Bologna, 23 October 2014 European Public Policies on CSR: The perceptions SMEs Eleni Apospori, Ph.D. Assistant Professor of.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Country Summary for Ukraine (part 1) status for Roman Volosyanchuk, IUCN CPC.
Sri Lanka Ministry of Indigenous Medicine.
Introduction to Prescription Analysis & Methodology
Critical Dimensions of Indian Investments in Africa (The IIA Project) 01 st PAC MEETING Vikash Batham 16th April, 2014, New Delhi.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
State Focus Group Dialogue 14 th September 2012, Kolkata Prithviraj Nath CUTS Calcutta Resource Centre Findings and Inferences from project-
National Quality Infrastructure TRTA3 Approach
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Issues in Health Sector Sanjib Pohit December 4, 2006.
National Policy Forum 8th October 2012, New Delhi Exploring the Interplay between Business Regulation and Corporate Conduct in India (BRCC Project) Project.
MODEL POLICY FRAMEWORK FOR E-WASTE MANAGEMENT IN THE EAST AFRICAN REGION Nakiguli Helen Cynthia, Uganda Communications Commission,
What GPOs are Doing to Promote Ethical Compliance Megan Barry VP, Ethics and Compliance Premier, Inc.
Chapter 7.2 Examination and Treatment Prepared by Nguyen Trong Khoa.
Interplay between business relations and corporate conduct in H.P. An update on Pharmaceuticals and Private Healthcare sectors Study by Gunjan Organisation.
1 Patient Safety In China Gao Xinqiang 23 June 2014.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
A COMPARISON OF PRESCRIBING PRACTICES BETWEEN PUBLIC AND PRIVATE SECTOR PHYSICIANS IN UGANDA Obua C, Ogwal-Okeng JW, WaakoP, Aupont O, Ross-Degnan D International.
Rethinking a Responsibility In India: a review of Pharmaceutical & Private Healthcare sectors BUSINESSES’ CONTRIBUTION TOWARDS GROWTH & SUSTAINABLE DEVELOPMENT.
Financial Sector Development: Building Market Foundations Through International Codes And Standards Sherman G. Boone, Assistant Director Office of International.
Trade & Access to Medicines in India Centre for Trade & Development
CLIENT PROVIDER RELATIONSHIP Presentation by :- Dr. RAJAT DAS -- Kolkata, WEST BENGAL INDIA.
Governance, Risk and Ethics. 2 Section A: Governance and responsibility Section B: Internal control and review Section C: Identifying and assessing risk.
Role of WHO as Technical Advisor to Ministry of Health West Bank and Gaza.
Introduction to Business Ethics CHAPTER 1 Business Ethics Instructor: sihem smida.
F Designed to give you knowledge and application of: Section A: Business organisational structure, governance & management A1. The business organisation.
A presentation by Charities Aid Foundation Australia John Winkett Deputy Director Charities Aid Foundation Australia.
From Jan 1, no freebies for docs from pharma firms.
Regulatory System of Research on New Infectious Diseases the Thai Perspective Soraj Hongladarom, Center for Ethics of Science and Technology Chulalongkorn.
Convening today at TIFR, Mumbai on 29th January, 2017, on the occasion of the Tata Memorial Centre Platinum Jubilee Conference – ‘Healthcare – a commodity.
Preventing Corruption & Bribery - Perspectives from the Regulators-
WHO Medicines Work in Countries: The Kenya Example
Pakistan ’s Overview Federal Capital: Islamabad
Harmonization of Policies recommendations for the integration of Sustainable consumption and production in the MED area.
La voix des Consommateurs à travers le monde
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
How can we make healthcare purchasing in Kenya more strategic?
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

National Policy Forum 8 th October 2012, New Delhi Prithviraj Nath CUTS Calcutta Resource Centre Findings and Inferences from project- BRCC (West Bengal) 1

Overview of Pharmaceutical Sector The genesis of Indian pharmaceutical industry is always traced back to 1901 West Bengal when scientist Acharya Prafulla Chandra Ray laid the foundation stones of Bengal Chemical & Pharmaceutical Works Ltd (BCPL). West Bengal saw the advent of many new pharmaceutical manufacturers during 1970s with the advent of the Patents Act and also encouraging Industrial policy by Govt. Of India. In 2005 product patent was first introduced and GMP was also introduced during this time. West Bengal saw a gradual decline in numbers of manufacturing units from around in early 90’s to in early 2000s to just around 166 at present. (Source: Directorate of Drug Control, West Bengal) Most of the firms, around 120, are situated in and around Kolkata, around 40 firms are located in North & South 24 Parganas and the rest in other districts of West Bengal. 2

Overview of Healthcare Sector The growth in private healthcare started picking up since the 1990s and introduction of National Health Policy 2002(Govt. of India) and PPP policy 2006(Govt. of West Bengal) boosted it. The total number of health units in the State is roughly around 2000 (leaving out sub-centres) including both private and public units. The number of private hospitals outnumber the public hospitals in the state by more than triple, while the proportion of hospital beds show a absolute reverse statistics with the government figures being more than double the private counterparts. more than triple, while the proportion of hospital beds show a absolute reverse statistics The average number of private health care institutions (excluding physician’s chambers) is 0.58 per 10,000 population in the municipal areas of West Bengal Kolkata has emerged as the healthcare hub in eastern India with around 121 leading nursing homes and 63 large hospitals. There are roughly 188 diagnostic centres in and around Kolkata. Other districts with appreciable presence of private healthcare are North & South 24 Parganas, Howrah, Hooghly, Bardhaman and East & West Midnapur. 3

Methodology for the survey Sample Composition: Pharmaceuticals - 50 Bulk drug manufacturers - 5 Formulations – 45 Private Hospitals ( 2:2:1 ratio was attempted) - 50 Big Hospitals (more than 100 beds) - 22 Medium Hospitals ( beds) - 16 Small Hospitals (15-30 beds) – 12 Medical Representatives - 40 Sectoral Associations – 6 Govt. Authorities and regulatory bodies-3 Local Community – 6 Prescriptions Analysed-305 Research Tools: (a) Questionnaire Survey (b)Focus Group Discussion Districts covered: Kolkata, North & South 24 Parganas,Nadia, Bardhaman,Jalpaiguri,Siliguri,Howrah. 4

Macro Level issues influencing Business Responsibility in the 2 sectors in the State Weak Regulatory Regime, more importantly the implementation thereof, to address the issue of unethical business practices in the face of intense competition. Stringent norms under GMP difficult for SME Pharmaceutical units – Counter Competitive. Lack of an appropriate HR policy for MRs. Lack of proactiveness and mandate among Business Associations to promote responsible business behaviour by their members. Government’s role was opined to be inadequate by many of the sectoral associations. 5

Evidence suggesting violation of ‘Business Responsibility’ in the pharmaceutical sector Majority of pharmaceutical surveyed units don’t have dedicated environment management department. Majority of pharmaceutical surveyed units don’t have dedicated environment management department. Pharmaceutical firms are mostly not willing to fix salaries of Medical representativesnot willing to fix salaries Low awareness on UCPMP, NVGs, etc. among pharmaceutical units Low awareness on UCPMP, NVGs, etc. 20 out of 50 pharmaceutical companies surveyed sponsor events like meeting, workshop, seminar etc for doctors. 20 out of 50 pharmaceutical companies surveyed sponsor events like meeting, workshop, seminar etc for doctors. Medical Representatives (MR) said that gifts are given to doctors though they may not ask for it Though many of the MRs were not forthcoming, some did agree that there is a nexus between doctors and pharmaceutical firms. Though many of the MRs were not forthcoming, some did agree that there is a nexus between doctors and pharmaceutical firms. 6

Communities’ Voice 7 Out of the 6 communities surveyed only 2 complained about environmental problems. They experience health related problems like headache, vomiting and the bad smell causes discomfort. Water bodies in the locality are also polluted. Weak monitoring and implementation and violation of guidelines by pharmaceutical firms lead to such problems. The community members fight these issues jointly through local club. Opined that industry should be located in special industrial zone.

Evidence suggesting violation of ‘Business Responsibility’ in the private healthcare sector On Regulations: Around 75% of the hospitals follow code of Optimal Healthcare Other guidelines like those on prescriptions, RUD, etc. are not so religiously followed. Other guidelines like those on prescriptions, RUD, etc. are not so religiously followed. Low awareness on UCPMP, NVGs, etc. among Hospitals Low awareness on UCPMP, NVGs, etc. Bigger hospitals seem slightly better off than medium and small hospitals in this respect Bigger hospitals seem slightly better off than medium and small hospitals in this respect 8

Prescription Analysis Auditable Prescription: 305 Total number of complete prescription: 14 Prescription not auditable: 22 (8 were illegible) Number of Drugs per prescription: 2.9 Rational Prescription: 1.96 % Irrational Prescription: % Prescription containing antibiotic: % Prescription containing Analgesics: % Average Costs per prescription per day: INR Most irrationally prescribed drugs were: (a) Antibiotics (b)NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) (c) PPI (Proton pump inhibitors, gastric acid reduction) (d) H2 Blockers (gastroesophageal reflux disease) (e) Vitamins (f) Antipsychotics (g)Antihistaminics (allergies) No banned drugs were prescribed 9

Corporate Social Responsibility 17% of the Pharma firms and 73% of the Hospitals have CSR policy. 17% of the Pharma firms and 73% of the Hospitals have CSR policy The reasons for having CSR activities has mostly to do with goodwill and image. Though hospitals seem to more inclined towards CSR as integral part of their business than Pharmaceuticals. The reasons for having CSR activities has mostly to do with goodwill and image. Though hospitals seem to more inclined towards CSR as integral part of their business than Pharmaceuticals Perception about business responsibility/CSR is mostly limited to charitable initiatives like medical camps, free treatment for the poor, etc. 10

Creating incentives for recognising and adopting business responsibility as part of the core business activity and taking penal actions for violation. Pharmaceutical Industry being a very important part of healthcare system needs proper surveillance of the Govt. specially the work conditions and job security of the MRs as these are the determinants of unethical practices. Detailed audit of the CME expenses of the pharmaceutical firms and audit of the income-expense of the service providers. Multi-stakeholder dialogues on important issues and specific guidelines to make policy making more participatory leading to higher ownership. Govt. can weigh down the cost of environmental externalities caused by smaller firms if the GMP norms are relaxed for them vis-à-vis the increasing retail price of medicines produced by the bigger firms and reconsider separate GMP norms for the smaller companies. Capacity building of private sector/industry on voluntary guidelines – charting a sector specific roadmap to this end 11 Recommendations

12 Higher involvement of Civil Society Organisations towards monitoring ethical & environmental concerns, spread awareness, demystifying technical & jargonised guidelines, rules for common consumers, redressal of grievances etc. to ensure higher transparency. Associations to more actively engage to help make the private sector more responsible and make them aware about the rules and regulations-inclusion of business responsibility clauses in the mandate of associations and periodic assessment with support/facilitation from Ministry of Corporate Affairs Compliance through better self-regulation, capacity building, better communication amongst all stakeholders and greater transparency by encouraging higher consumer understanding and participation. To realise that strong corporate governance and responsible business conduct brings better transparency and better credit rating, goodwill etc. which in turn help them gain financially as well.

THANK YOU 13

14 Awareness among Pharma Companies on Selected Regulations and Guidelines

15 Do you have any dedicated Environmental management department in your firm? Do you have any infrastructure in place to reduce negative environmental effects? Do you think that implementation of regulatory laws should be done differently depending on the size and nature of the unit?

16 Perception of Pharmaceutical companies about implication of salary structure on Ethical behaviour and areas of ethical concern

17

18

Compliance with selected Guidelines by Private Hospitals

20 Awareness among Private Hospitals on Selected Regulations and Guidelines

21

22

23